Relationship between the dose and whole blood level of cyclosporine after liver and kidney transplantation
- PMID: 1339916
Relationship between the dose and whole blood level of cyclosporine after liver and kidney transplantation
Abstract
Descriptions of the immunosuppression protocols used after organ transplantation typically refer to the dose of cyclosporine (on a per weight basis) given to patients. In actual clinical practice, however, the amount of cyclosporine given to patients is determined principally by the concentration of the drug present in blood. In this study we determined the correlation between the dose of cyclosporine prescribed and the level of cyclosporine achieved in stable organ recipients three or more months following successful grafting. Seventy-five adult liver transplant recipients and 65 kidney transplant recipients who survived for more than three months after the transplant and who had stable graft function were included in the analysis. The cyclosporine dose and the cyclosporine level at the first out-patient visit were recorded for each patient. The median dose of cyclosporine used in liver recipients was 15 mg/kg/day. Seventeen percent of liver transplant recipients were on a maintenance dose of cyclosporine of less than 12 mg/kg/day. Fifteen percent were on a maintenance dose of greater than 22 mg/kg/day. The median dose utilized by kidney transplant recipients was 15 mg/kg/day. Twenty-eight percent of kidney recipients were on a maintenance dose of less than 12 mg/kg/day while 9% were taking more than 22 mg/kg/day. The median whole blood cyclosporine level in liver recipients was 1025 ng/ml (range 18-1925 ng/ml). The median level in kidney recipients was 542 ng/ml (range 79-1451 ng/ml). The majority of the liver and kidney recipients had cyclosporine levels within standard "therapeutic" ranges reported for each type of transplant.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.Liver Transpl. 2002 Mar;8(3):212-8. doi: 10.1053/jlts.2002.31346. Liver Transpl. 2002. PMID: 11910565
-
Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.J Med Assoc Thai. 2006 Aug;89 Suppl 2:S15-20. J Med Assoc Thai. 2006. PMID: 17044449 Clinical Trial.
-
Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.Transplant Proc. 2008 Sep;40(7):2245-51. doi: 10.1016/j.transproceed.2008.06.044. Transplant Proc. 2008. PMID: 18790205
-
Gene expression profiling and transplantation tolerance in the clinic.Transplantation. 2009 Aug 15;88(3 Suppl):S50-3. doi: 10.1097/TP.0b013e3181af7d17. Transplantation. 2009. PMID: 19667962 Review.
-
[Regressive leukoencephalopathy induced by an overdose of cyclosporine A].Rev Neurol (Paris). 1993;149(10):576-8. Rev Neurol (Paris). 1993. PMID: 8023077 Review. French.
Cited by
-
Use of human organ slices to evaluate the biotransformation and drug-induced side-effects of pharmaceuticals.Cell Biol Toxicol. 1994 Dec;10(5-6):407-14. doi: 10.1007/BF00755790. Cell Biol Toxicol. 1994. PMID: 7697504
-
The use of therapeutic drug monitoring to optimise immunosuppressive therapy.Clin Pharmacokinet. 1996 Feb;30(2):107-40. doi: 10.2165/00003088-199630020-00003. Clin Pharmacokinet. 1996. PMID: 8906895 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical